Assessment, Risk Stratification, and Treatment of Advanced CSCC: The Importance of Dermatology/Oncology Care Coordination to Improve Patient Outcomes

Approximately 1 million individuals are affected by cutaneous squamous cell carcinoma (CSCC) in the US each year. Although locoregional or distant metastatic disease occurs in only 1% to 5% of cases, mortality in these individuals is high. The management of CSCC has traditionally been a key component of the dermatology practice; however, with the recent FDA approval of immunotherapies for advanced CSCC, medical oncologists are playing a greater role in the management of these patients. This educational activity, which includes 2 publications, discusses the importance of the multidisciplinary team in the management of advanced CSCC. One activity, developed for dermatologists, is focused on risk assessment, staging, and current and emerging treatments in advanced CSCC. The other activity, developed for oncologists, reviews the safety, efficacy, and mechanism of action for the FDA-approved immunotherapies.


Lara Dunn, MD
Medical Oncologist
Memorial Sloan Kettering Cancer Center
New York, NY

Nikhil I. Khushalani, MD
Vice Chair and Senior Member, Department of Cutaneous Oncology
Moffitt Cancer Center
Tampa, FL

Badri Modi, MD
Assistant Clinical Professor, Division of Dermatology
Department of Surgery
City of Hope Comprehensive Cancer Center
Duarte, CA